Wednesday, October 29, 2008

New allergy and asthma drugs update October 2008

I have seen two changes since my last update.
1. Symbicort inhaler has a new actuator device. It has a built-in dose-counter. I have no experience with this device through clinical trials. Reportedly, every patient will receive this device automatically when they fill a Symbicort 160/4.5 script. AstraZeneca, the manufacturer, plans to begin marketing Symbicort 80/4.5 inhalers with a built-in counter in January of 2009. Built-in dose-counters are a good idea. Three other inhaled corticosteroids have one also: Advair, Asmanex, Pulmicort Flexhaler, not Qvar.
2. The F.D.A. approved Astepro on 10/10/08, which is a new formulation of Astelin, for the treatment of seasonal allergic rhinitis. Astepro Nasal Spray is supposed to be an improvement over the marketed Astelin Nasal Spray because it should be better tolerated by patients. The active substance in both of these products is azelastine. In phase 3 studies, fewer subjects reported bitter taste and nasal discomfort from Astepro user compared to Astelin. Symptom relief, as recorded by patients, was also better. In total, about 1,400 patients were involved in Meda's phase III studies. I have no direct experience with Astepro through clinical trials. No word on when the product will be marketed.

1 comment:

Anonymous said...

Don’t neglect your Enlarged prostate disease because it can lead to renal failure termed as obstructive uropathy. If you want to avoid urinary bladder stone formation that may be caused by increase of prostate size, then adopt Avodart earlier. Buy Avodart;シアリス,アボダート

This website is certified by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information: verify here.
 
My Zimbio Medicine Blogs - BlogCatalog Blog Directory